Escitalopram--translating molecular properties into clinical benefit: reviewing the evidence in major depression.
AffiliationDepartment of Pharmacology, National University of Ireland, Galway, Ireland.
Depressive Disorder, Major
Meta-Analysis as Topic
Randomized Controlled Trials as Topic
Serotonin Uptake Inhibitors
MetadataShow full item record
CitationEscitalopram--translating molecular properties into clinical benefit: reviewing the evidence in major depression. 2010, 24 (8):1143-52 J. Psychopharmacol. (Oxford)
JournalJournal of psychopharmacology (Oxford, England)
AbstractThe majority of currently marketed drugs contain a mixture of enantiomers; however, recent evidence suggests that individual enantiomers can have pharmacological properties that differ importantly from enantiomer mixtures. Escitalopram, the S-enantiomer of citalopram, displays markedly different pharmacological activity to the R-enantiomer. This review aims to evaluate whether these differences confer any significant clinical advantage for escitalopram over either citalopram or other frequently used antidepressants. Searches were conducted using PubMed and EMBASE (up to January 2009). Abstracts of the retrieved studies were reviewed independently by both authors for inclusion. Only those studies relating to depression or major depressive disorder were included. The search identified over 250 citations, of which 21 studies and 18 pooled or meta-analyses studies were deemed suitable for inclusion. These studies reveal that escitalopram has some efficacy advantage over citalopram and paroxetine, but no consistent advantage over other selective serotonin reuptake inhibitors. Escitalopram has at least comparable efficacy to available serotonin-norepinephrine reuptake inhibitors, venlafaxine XR and duloxetine, and may offer some tolerability advantages over these agents. This review suggests that the mechanistic advantages of escitalopram over citalopram translate into clinical efficacy advantages. Escitalopram may have a favourable benefit-risk ratio compared with citalopram and possibly with several other antidepressant agents.
- Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis.
- Authors: Kennedy SH, Andersen HF, Lam RW
- Issue date: 2006 Mar
- Escitalopram versus citalopram: the surprising role of the R-enantiomer.
- Authors: Sánchez C, Bøgesø KP, Ebert B, Reines EH, Braestrup C
- Issue date: 2004 Jul
- Escitalopram versus serotonin noradrenaline reuptake inhibitors as second step treatment for patients with major depressive disorder: a pooled analysis.
- Authors: Lam RW, Lönn SL, Despiégel N
- Issue date: 2010 Jul
- Escitalopram in the treatment of major depressive disorder: clinical efficacy, tolerability and cost-effectiveness vs. venlafaxine extended-release formulation.
- Authors: Llorca PM, Fernandez JL
- Issue date: 2007 Apr
- Newer antidepressants: review of efficacy and safety of escitalopram and duloxetine.
- Authors: Hirschfeld RM, Vornik LA
- Issue date: 2004